Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophageal Neoplasms | 4 | 2023 | 1583 | 1.680 |
Why?
|
Data Interpretation, Statistical | 9 | 2020 | 2716 | 1.560 |
Why?
|
Proportional Hazards Models | 15 | 2022 | 12354 | 1.520 |
Why?
|
Survival Analysis | 14 | 2022 | 10252 | 1.460 |
Why?
|
Trifluridine | 2 | 2019 | 29 | 1.300 |
Why?
|
Hyperthermia, Induced | 2 | 2023 | 403 | 1.250 |
Why?
|
Medical Oncology | 5 | 2023 | 2265 | 1.210 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2728 | 1.210 |
Why?
|
Randomized Controlled Trials as Topic | 16 | 2021 | 9959 | 1.210 |
Why?
|
Stomach Neoplasms | 3 | 2021 | 1333 | 1.150 |
Why?
|
Rectal Neoplasms | 3 | 2021 | 1206 | 1.100 |
Why?
|
Esophagectomy | 3 | 2023 | 447 | 0.970 |
Why?
|
Lung Neoplasms | 9 | 2022 | 13102 | 0.930 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2024 | 56 | 0.930 |
Why?
|
Breast Neoplasms | 12 | 2022 | 20822 | 0.910 |
Why?
|
Muscular Dystrophy, Duchenne | 3 | 2021 | 256 | 0.910 |
Why?
|
Oxadiazoles | 2 | 2020 | 93 | 0.900 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7913 | 0.880 |
Why?
|
Cardiovascular Diseases | 12 | 2023 | 15165 | 0.870 |
Why?
|
Drug-Eluting Stents | 2 | 2019 | 753 | 0.850 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5221 | 0.850 |
Why?
|
Research Design | 6 | 2022 | 5987 | 0.830 |
Why?
|
Nose Neoplasms | 1 | 2024 | 246 | 0.800 |
Why?
|
Humans | 124 | 2024 | 744343 | 0.790 |
Why?
|
Immunotherapy | 5 | 2022 | 4445 | 0.780 |
Why?
|
Neoplasms | 10 | 2022 | 21683 | 0.770 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6538 | 0.770 |
Why?
|
Survival Rate | 10 | 2021 | 12788 | 0.720 |
Why?
|
Aromatase | 1 | 2020 | 146 | 0.710 |
Why?
|
Treatment Outcome | 24 | 2022 | 63114 | 0.700 |
Why?
|
Colonic Neoplasms | 2 | 2023 | 2541 | 0.690 |
Why?
|
Adenocarcinoma | 3 | 2023 | 6364 | 0.660 |
Why?
|
Head and Neck Neoplasms | 2 | 2024 | 2734 | 0.630 |
Why?
|
Paclitaxel | 3 | 2023 | 1708 | 0.620 |
Why?
|
Rifampin | 1 | 2019 | 315 | 0.610 |
Why?
|
Propanolamines | 1 | 2018 | 167 | 0.610 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2018 | 1240 | 0.590 |
Why?
|
Patient Care Management | 1 | 2020 | 306 | 0.590 |
Why?
|
Epoetin Alfa | 1 | 2016 | 83 | 0.570 |
Why?
|
Blood Pressure Determination | 2 | 2023 | 634 | 0.570 |
Why?
|
Lymph Node Excision | 2 | 2023 | 1261 | 0.550 |
Why?
|
Taxoids | 2 | 2018 | 666 | 0.550 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2022 | 1205 | 0.540 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2024 | 4034 | 0.530 |
Why?
|
Digestive System Surgical Procedures | 1 | 2021 | 576 | 0.520 |
Why?
|
Hypertension | 5 | 2023 | 8480 | 0.520 |
Why?
|
Axilla | 1 | 2018 | 595 | 0.520 |
Why?
|
Anticholesteremic Agents | 2 | 2020 | 979 | 0.520 |
Why?
|
Therapeutics | 1 | 2015 | 116 | 0.520 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 681 | 0.510 |
Why?
|
Prostatic Neoplasms | 4 | 2022 | 11124 | 0.480 |
Why?
|
Endpoint Determination | 3 | 2023 | 601 | 0.460 |
Why?
|
Urologic Neoplasms | 1 | 2017 | 318 | 0.450 |
Why?
|
Statistics as Topic | 3 | 2020 | 2373 | 0.450 |
Why?
|
Confidence Intervals | 3 | 2020 | 2971 | 0.430 |
Why?
|
Standard of Care | 1 | 2016 | 564 | 0.430 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 11524 | 0.430 |
Why?
|
Vascular Diseases | 1 | 2020 | 1161 | 0.420 |
Why?
|
Drug Therapy | 1 | 2015 | 497 | 0.420 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.420 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.410 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 3143 | 0.390 |
Why?
|
Longitudinal Studies | 4 | 2024 | 13989 | 0.390 |
Why?
|
Quinolines | 1 | 2016 | 732 | 0.380 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 6773 | 0.380 |
Why?
|
Decision Support Techniques | 1 | 2021 | 1956 | 0.380 |
Why?
|
Neoplasms, Second Primary | 1 | 2019 | 1061 | 0.380 |
Why?
|
Statistical Distributions | 1 | 2010 | 64 | 0.380 |
Why?
|
Bone Density Conservation Agents | 1 | 2018 | 773 | 0.380 |
Why?
|
Biometry | 2 | 2010 | 558 | 0.370 |
Why?
|
Pandemics | 2 | 2020 | 8388 | 0.360 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1972 | 0.350 |
Why?
|
Receptor, erbB-2 | 4 | 2022 | 2416 | 0.350 |
Why?
|
Kidney Neoplasms | 2 | 2024 | 4262 | 0.350 |
Why?
|
Melanoma | 2 | 2018 | 5510 | 0.350 |
Why?
|
Consensus | 1 | 2018 | 2959 | 0.340 |
Why?
|
Soft Tissue Neoplasms | 1 | 2019 | 1363 | 0.340 |
Why?
|
Antihypertensive Agents | 5 | 2023 | 2046 | 0.340 |
Why?
|
Adiposity | 1 | 2019 | 1807 | 0.330 |
Why?
|
Carcinoma | 1 | 2020 | 2375 | 0.330 |
Why?
|
Dementia | 2 | 2021 | 2518 | 0.330 |
Why?
|
Thymine | 2 | 2019 | 68 | 0.330 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5686 | 0.320 |
Why?
|
Aminopyridines | 2 | 2022 | 542 | 0.310 |
Why?
|
Thiazolidinediones | 1 | 2011 | 476 | 0.300 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3523 | 0.300 |
Why?
|
Sarcoma | 1 | 2019 | 1897 | 0.300 |
Why?
|
MicroRNAs | 1 | 2023 | 3752 | 0.290 |
Why?
|
Sample Size | 3 | 2015 | 845 | 0.290 |
Why?
|
Laparoscopy | 1 | 2019 | 2151 | 0.290 |
Why?
|
Tuberculosis | 1 | 2019 | 1912 | 0.290 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1671 | 0.280 |
Why?
|
Pyrrolidines | 2 | 2019 | 342 | 0.280 |
Why?
|
Acute Coronary Syndrome | 1 | 2020 | 2337 | 0.280 |
Why?
|
Benzimidazoles | 2 | 2022 | 850 | 0.280 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4838 | 0.270 |
Why?
|
Heart Failure | 6 | 2023 | 10900 | 0.270 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2022 | 3479 | 0.240 |
Why?
|
Time Factors | 9 | 2021 | 40075 | 0.240 |
Why?
|
Area Under Curve | 2 | 2018 | 1654 | 0.240 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 2872 | 0.230 |
Why?
|
Patient Selection | 1 | 2015 | 4215 | 0.230 |
Why?
|
Drug Combinations | 2 | 2019 | 1959 | 0.220 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2020 | 3068 | 0.220 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2021 | 841 | 0.200 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5256 | 0.200 |
Why?
|
Nasal Cavity | 1 | 2024 | 313 | 0.200 |
Why?
|
Cause of Death | 2 | 2019 | 3584 | 0.200 |
Why?
|
Double-Blind Method | 5 | 2019 | 12026 | 0.200 |
Why?
|
Myocardial Infarction | 4 | 2021 | 11727 | 0.190 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 193 | 0.190 |
Why?
|
Prostate-Specific Antigen | 2 | 2022 | 2494 | 0.190 |
Why?
|
Liver Cirrhosis, Biliary | 2 | 2012 | 97 | 0.190 |
Why?
|
Multiple Myeloma | 1 | 2018 | 5181 | 0.190 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5442 | 0.190 |
Why?
|
Risk Assessment | 5 | 2019 | 23338 | 0.190 |
Why?
|
Models, Theoretical | 1 | 2012 | 3589 | 0.180 |
Why?
|
Fallopian Tubes | 1 | 2020 | 182 | 0.180 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13695 | 0.180 |
Why?
|
Stroke | 1 | 2022 | 9981 | 0.180 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 6487 | 0.170 |
Why?
|
Models, Statistical | 5 | 2022 | 5102 | 0.170 |
Why?
|
Lymph Nodes | 2 | 2023 | 3474 | 0.170 |
Why?
|
Piperazines | 2 | 2021 | 2488 | 0.170 |
Why?
|
Bryostatins | 1 | 2019 | 24 | 0.170 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2019 | 25 | 0.170 |
Why?
|
Codon, Nonsense | 1 | 2020 | 281 | 0.170 |
Why?
|
Neoplasm Staging | 2 | 2024 | 11031 | 0.170 |
Why?
|
Female | 25 | 2023 | 380194 | 0.160 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 292 | 0.160 |
Why?
|
Blood Pressure | 4 | 2023 | 8554 | 0.160 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9274 | 0.160 |
Why?
|
Phthalazines | 1 | 2021 | 363 | 0.160 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 275 | 0.160 |
Why?
|
Hormones | 1 | 2022 | 889 | 0.160 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.160 |
Why?
|
Aspirin | 2 | 2020 | 3282 | 0.160 |
Why?
|
Isoniazid | 1 | 2019 | 274 | 0.150 |
Why?
|
Immunization, Passive | 1 | 2020 | 623 | 0.150 |
Why?
|
Asthma | 1 | 2016 | 6011 | 0.150 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2020 | 367 | 0.150 |
Why?
|
Cisplatin | 1 | 2023 | 1662 | 0.150 |
Why?
|
Intensive Care Units | 2 | 2021 | 3679 | 0.150 |
Why?
|
Anastomosis, Surgical | 1 | 2021 | 987 | 0.150 |
Why?
|
Nitriles | 1 | 2022 | 956 | 0.150 |
Why?
|
Simvastatin | 1 | 2020 | 360 | 0.150 |
Why?
|
Stents | 2 | 2019 | 3280 | 0.150 |
Why?
|
Republic of Korea | 1 | 2019 | 539 | 0.150 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2019 | 339 | 0.150 |
Why?
|
Uracil | 1 | 2018 | 165 | 0.150 |
Why?
|
Hepatitis B, Chronic | 2 | 2014 | 393 | 0.140 |
Why?
|
Positive-Pressure Respiration | 1 | 2021 | 633 | 0.140 |
Why?
|
Absorbable Implants | 1 | 2019 | 342 | 0.140 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1677 | 0.140 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2019 | 361 | 0.140 |
Why?
|
Pravastatin | 1 | 2018 | 395 | 0.140 |
Why?
|
Random Allocation | 1 | 2021 | 2429 | 0.140 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 491 | 0.140 |
Why?
|
Male | 20 | 2023 | 350118 | 0.140 |
Why?
|
Monte Carlo Method | 2 | 2012 | 1254 | 0.140 |
Why?
|
Indazoles | 1 | 2017 | 289 | 0.130 |
Why?
|
Observation | 1 | 2017 | 312 | 0.130 |
Why?
|
Albuterol | 1 | 2016 | 208 | 0.130 |
Why?
|
Deoxycytidine | 1 | 2019 | 826 | 0.130 |
Why?
|
Prognosis | 4 | 2019 | 29063 | 0.130 |
Why?
|
Adrenergic beta-Agonists | 1 | 2016 | 346 | 0.130 |
Why?
|
Independent Living | 1 | 2019 | 568 | 0.120 |
Why?
|
Probability | 1 | 2020 | 2505 | 0.120 |
Why?
|
Metals | 1 | 2019 | 719 | 0.120 |
Why?
|
Body Composition | 2 | 2019 | 2401 | 0.120 |
Why?
|
Gastrectomy | 1 | 2019 | 663 | 0.120 |
Why?
|
Rare Diseases | 1 | 2019 | 553 | 0.120 |
Why?
|
Rectum | 1 | 2019 | 904 | 0.120 |
Why?
|
Histocytochemistry | 1 | 2014 | 719 | 0.120 |
Why?
|
Hematinics | 1 | 2016 | 281 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.120 |
Why?
|
Administration, Inhalation | 1 | 2016 | 1105 | 0.110 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 2124 | 0.110 |
Why?
|
Spinal Curvatures | 1 | 2014 | 66 | 0.110 |
Why?
|
Nursing Homes | 1 | 2021 | 1036 | 0.110 |
Why?
|
Braces | 1 | 2014 | 135 | 0.110 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2018 | 709 | 0.110 |
Why?
|
Diphosphonates | 1 | 2018 | 623 | 0.110 |
Why?
|
Patient Admission | 1 | 2021 | 1380 | 0.110 |
Why?
|
Bronchodilator Agents | 1 | 2016 | 502 | 0.110 |
Why?
|
Estrogens | 1 | 2020 | 1566 | 0.110 |
Why?
|
Esophagus | 1 | 2019 | 1019 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1038 | 0.110 |
Why?
|
Immunologic Factors | 1 | 2022 | 1580 | 0.110 |
Why?
|
Penicillamine | 1 | 2012 | 59 | 0.100 |
Why?
|
Incidence | 2 | 2022 | 20947 | 0.100 |
Why?
|
Erythropoietin | 1 | 2016 | 726 | 0.100 |
Why?
|
Disease-Free Survival | 1 | 2022 | 6895 | 0.100 |
Why?
|
Polymers | 1 | 2019 | 1621 | 0.100 |
Why?
|
Anti-Asthmatic Agents | 1 | 2016 | 536 | 0.100 |
Why?
|
Sirolimus | 1 | 2019 | 1564 | 0.100 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8642 | 0.100 |
Why?
|
Primary Prevention | 1 | 2018 | 1167 | 0.100 |
Why?
|
Hemoglobins | 1 | 2016 | 1534 | 0.090 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3670 | 0.090 |
Why?
|
Biostatistics | 1 | 2012 | 162 | 0.090 |
Why?
|
Survivors | 1 | 2020 | 2291 | 0.090 |
Why?
|
Elasticity Imaging Techniques | 1 | 2014 | 388 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1620 | 0.090 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3610 | 0.090 |
Why?
|
Natriuretic Agents | 1 | 2009 | 25 | 0.090 |
Why?
|
Nonlinear Dynamics | 1 | 2012 | 502 | 0.080 |
Why?
|
Aged | 10 | 2024 | 163280 | 0.080 |
Why?
|
Sulfonamides | 1 | 2017 | 1938 | 0.080 |
Why?
|
Heart Rate | 1 | 2019 | 4091 | 0.080 |
Why?
|
Bone and Bones | 1 | 2018 | 2575 | 0.070 |
Why?
|
Pyridines | 1 | 2019 | 2825 | 0.070 |
Why?
|
Anemia | 1 | 2016 | 1506 | 0.070 |
Why?
|
Markov Chains | 1 | 2010 | 969 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6622 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2727 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2864 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2021 | 11725 | 0.070 |
Why?
|
Nucleosides | 1 | 2007 | 138 | 0.070 |
Why?
|
Hepatitis C, Chronic | 1 | 2014 | 1031 | 0.070 |
Why?
|
Carboxypeptidases | 1 | 2006 | 176 | 0.070 |
Why?
|
Stroke Volume | 1 | 2019 | 5007 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2011 | 1344 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3703 | 0.070 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 517 | 0.060 |
Why?
|
Pyrimidines | 1 | 2017 | 2942 | 0.060 |
Why?
|
Aortic Valve Stenosis | 1 | 2017 | 1965 | 0.060 |
Why?
|
Abdominal Fat | 1 | 2006 | 223 | 0.060 |
Why?
|
Naphthoquinones | 1 | 2004 | 77 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2023 | 19905 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1863 | 0.060 |
Why?
|
Decision Making | 1 | 2018 | 3887 | 0.060 |
Why?
|
Exons | 1 | 2010 | 2437 | 0.060 |
Why?
|
Coronary Disease | 1 | 2018 | 6077 | 0.060 |
Why?
|
Creatinine | 1 | 2009 | 1919 | 0.060 |
Why?
|
Azithromycin | 1 | 2004 | 196 | 0.060 |
Why?
|
Thrombolytic Therapy | 1 | 2013 | 2161 | 0.060 |
Why?
|
Child | 3 | 2023 | 77709 | 0.060 |
Why?
|
Nevirapine | 1 | 2004 | 267 | 0.060 |
Why?
|
Gene Frequency | 1 | 2010 | 3588 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2012 | 6365 | 0.050 |
Why?
|
Linkage Disequilibrium | 1 | 2007 | 1997 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2010 | 2309 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2007 | 15519 | 0.050 |
Why?
|
Algorithms | 4 | 2021 | 13881 | 0.050 |
Why?
|
Computer Simulation | 1 | 2015 | 6196 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5535 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2004 | 684 | 0.050 |
Why?
|
Adult | 8 | 2022 | 214055 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2004 | 657 | 0.050 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2009 | 1573 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10262 | 0.050 |
Why?
|
Prednisolone | 1 | 2021 | 334 | 0.050 |
Why?
|
Quality of Life | 2 | 2024 | 12804 | 0.050 |
Why?
|
HIV Infections | 3 | 2018 | 16718 | 0.040 |
Why?
|
Cholinesterase Inhibitors | 1 | 2021 | 238 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39050 | 0.040 |
Why?
|
Iceland | 1 | 2019 | 183 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2004 | 3920 | 0.040 |
Why?
|
Alzheimer Disease | 1 | 2019 | 8037 | 0.040 |
Why?
|
Prospective Studies | 2 | 2019 | 53288 | 0.040 |
Why?
|
Benzhydryl Compounds | 1 | 2023 | 845 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2004 | 1431 | 0.040 |
Why?
|
Genetic Variation | 2 | 2010 | 6544 | 0.040 |
Why?
|
Pre-Eclampsia | 1 | 2006 | 1200 | 0.040 |
Why?
|
Prednisone | 1 | 2021 | 1574 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 2 | 2018 | 2559 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 12745 | 0.030 |
Why?
|
Patient Dropouts | 1 | 2019 | 421 | 0.030 |
Why?
|
Middle Aged | 7 | 2019 | 213383 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2004 | 1401 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20129 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2618 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2007 | 2987 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2018 | 1873 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2274 | 0.030 |
Why?
|
Models, Genetic | 3 | 2010 | 3494 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2004 | 2026 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2004 | 4803 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2004 | 9438 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8324 | 0.020 |
Why?
|
Gene Expression | 2 | 2018 | 7799 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2019 | 2418 | 0.020 |
Why?
|
Genetic Markers | 2 | 2007 | 2634 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3299 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2004 | 4256 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3527 | 0.020 |
Why?
|
Hepatitis B e Antigens | 1 | 2007 | 133 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10943 | 0.020 |
Why?
|
Angiotensinogen | 1 | 2006 | 163 | 0.020 |
Why?
|
Guanine | 1 | 2007 | 274 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6442 | 0.020 |
Why?
|
Lamivudine | 1 | 2007 | 342 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 2004 | 4740 | 0.020 |
Why?
|
Atovaquone | 1 | 2004 | 58 | 0.020 |
Why?
|
Genetics, Population | 1 | 2010 | 934 | 0.020 |
Why?
|
Rural Health | 1 | 2006 | 305 | 0.020 |
Why?
|
Nelfinavir | 1 | 2004 | 68 | 0.020 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2006 | 365 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2007 | 629 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 57776 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2004 | 249 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 2009 | 804 | 0.010 |
Why?
|
Liver Failure, Acute | 1 | 2004 | 165 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6756 | 0.010 |
Why?
|
Interferon-alpha | 1 | 2007 | 895 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13284 | 0.010 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2004 | 403 | 0.010 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2004 | 354 | 0.010 |
Why?
|
Adenine | 1 | 2007 | 936 | 0.010 |
Why?
|
Renin-Angiotensin System | 1 | 2006 | 759 | 0.010 |
Why?
|
Cognition | 1 | 2019 | 6770 | 0.010 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2004 | 280 | 0.010 |
Why?
|
China | 1 | 2006 | 2248 | 0.010 |
Why?
|
Absorptiometry, Photon | 1 | 2006 | 1725 | 0.010 |
Why?
|
HIV-1 | 1 | 2018 | 6939 | 0.010 |
Why?
|
Safety | 1 | 2004 | 1186 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2004 | 2256 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2007 | 21746 | 0.010 |
Why?
|
Administration, Oral | 1 | 2007 | 3913 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2004 | 1758 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2004 | 2715 | 0.010 |
Why?
|
Health Surveys | 1 | 2006 | 4037 | 0.010 |
Why?
|
Rural Population | 1 | 2006 | 2210 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 3616 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 6489 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2004 | 25625 | 0.010 |
Why?
|
Odds Ratio | 1 | 2006 | 9849 | 0.010 |
Why?
|
Pregnancy | 2 | 2006 | 29144 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 7186 | 0.010 |
Why?
|
Boston | 1 | 2006 | 9313 | 0.010 |
Why?
|
Sex Factors | 1 | 2006 | 10397 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 72290 | 0.010 |
Why?
|
Genotype | 1 | 2006 | 12951 | 0.010 |
Why?
|
Chronic Disease | 1 | 2006 | 9146 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12261 | 0.010 |
Why?
|
Genetic Testing | 1 | 2004 | 3444 | 0.010 |
Why?
|
Age Factors | 1 | 2006 | 18370 | 0.010 |
Why?
|
Software | 1 | 2004 | 4443 | 0.010 |
Why?
|
Body Mass Index | 1 | 2006 | 12720 | 0.010 |
Why?
|
Phenotype | 1 | 2006 | 16365 | 0.010 |
Why?
|
United States | 1 | 2014 | 69872 | 0.000 |
Why?
|
Infant | 1 | 2004 | 35136 | 0.000 |
Why?
|
Child, Preschool | 1 | 2004 | 41006 | 0.000 |
Why?
|
Adolescent | 1 | 2004 | 85781 | 0.000 |
Why?
|